Real‐World Long‐Term Outcomes of Rezūm Therapy for Large‐Volume Benign Prostatic Hyperplasia: A Multicenter Cohort Study
Abstract
Benign prostatic hyperplasia (BPH) is a common cause of lower urinary tract symptoms (LUTS) in aging men. Patients with large prostates (≥ 80 mL) often experience more severe symptoms and have limited minimally invasive treatment options. Water vapor thermal therapy (Rezūm) has demonstrated efficacy in moderate‐sized glands, and emerging evidence including multicenter cohorts and systematic reviews suggests efficacy in larger glands. However, long‐term real‐world multicenter data remain limited. This study evaluates the effectiveness of Rezūm therapy in men urinary status outcomes, sexual function, and prostate size in a large, multicenter real‐world cohort with extended follow‐up.
Read the paper
Related studies
- Treatment of non-metastatic castration-resistant prostate cancer: facing age-related comorbidities and drug–drug interactions
- The Efficacy of Flogofilm® in the Treatment of Chronic Bacterial Prostatitis as an Adjuvant to Antibiotic Therapy: A Randomized Prospective Trial
- Inhibition of growth and contraction in human prostate stromal cells by silencing of NUAK1 and -2, and by the presumed NUAK inhibitors HTH01-015 and WZ4003
- Effectiveness and Safety of a New Nutrient Fixed Combination Containing Pollen Extract Plus Teupolioside, in the Management of LUTS in Patients with Benign Prostatic Hypertrophy: A Pilot Study
- Extract from Cucurbita pepo improves BPH symptoms without affecting sexual function: a 24-month noninterventional study
- Aquablation vs. holmium laser enucleation of the prostate for benign prostatic hyperplasia: a 150-patients prospective comparative multicenter study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.